AmberGen enables drug developers to see where their therapeutics distribute in tissue and determine whether they are driving the intended biological response. Our platform spatially maps small molecule drugs, antibody-based therapeutics, and oligonucleotide drugs alongside five complementary molecular layers—proteins, RNA, lipids, metabolites, and glycans—from the same tissue section. By aligning regional drug distribution with disease biology, we connect exposure to effect within intact tissue architecture. Powered by AI-driven analytics, AmberGen converts complex tissue data into actionable mechanistic insight that strengthens mechanism validation, informs development decisions, and reduces translational risk across programs.